Skip to main content
. 2020 Jul 31;6(31):eaay9131. doi: 10.1126/sciadv.aay9131

Fig. 2. PL inhibits mTORC1-high tumor growth in vivo.

Fig. 2

(A) The effect of PL on OVCAR-8 xenograft. PL (7 mg/kg) was administered intraperitoneally everyday to nude mice injected with OVCAR-8 cells. Eight mice per group were used. (B) The effect of PL on SW480 xenograft. PL (7 mg/kg) was administered intraperitoneally everyday to nude mice injected with SW480 shControl and SW480 shTSC2 cells. Eight mice per group were used. (C) The effect of PL on colon cancer PDX. PL (7 mg/kg) was administered intraperitoneally everyday to female SCID mice implanted with HJG152, HJG172, or HJG78 tumors. Seven mice per group for HJG152 and HJG78 and six mice per group for HJG172 were used. (D) The effect of PL on lung cancer PDX. PL (7 mg/kg) was administered intraperitoneally everyday to female severe combined immunodeficient (SCID) mice implanted with LG70, LG43, or LG55 tumors. Six mice per group for LG70 and seven mice per group for LG43 and LG55 were used. (E) The effect of PL on esophageal cancer PDX. PL (7 mg/kg) was administered intraperitoneally everyday to female SCID mice implanted with LEG139, LEG8, or LEG110 tumors. Seven mice per group for LEG139 and LEG8 and five mice per group for LEG110 were used. The volume and weight were measured as described in Materials and Methods. All data are presented as means ± SD (one-way ANOVA; *P < 0.05, **P < 0.01, significant difference compared to the vehicle group.)